about
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolMolecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayTumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapyPolymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AVariation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotypeFrequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.Long term survival in children with acute leukaemia and complications requiring mechanical ventilation.Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia riskConsolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseMyeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agendaGain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.New treatment strategies in childhood acute lymphoblastic leukaemia.Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia.Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.Clinical significance of aberrant DNA methylation in childhood acute lymphoblastic leukemia.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcomeOutcome of treatment in children with hypodiploid acute lymphoblastic leukemia.Childhood and adolescent lymphoid and myeloid leukemia.Acute lymphoblastic leukemia and Klinefelter syndrome in children: two cases and review of the literature.Outcomes after induction failure in childhood acute lymphoblastic leukemia.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaGenomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyTime point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia.Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary TherapyCloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.Treatment of childhood acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.
P50
Q23749304-664FCAE6-FBC8-45CD-BAB9-9913A8B80C29Q24650855-0F9F4B3D-9184-4042-AB30-70EC5B37D413Q24798344-A1D11058-EFF3-4BCE-95EB-EB678EFD3BC9Q24814207-E874AEFA-D0A8-4377-9F7C-37286B6E2784Q27852750-2327BEE3-9C42-44F8-99E4-185F143A8CB3Q28391081-BDD0F0C8-76D4-45FB-9DBE-DC43124AF368Q28943255-BD9CFA77-0881-4D4D-B5EE-349AE57B9F21Q33587619-0257270E-97F3-4981-A782-D1259AB9A61AQ33947700-C721E807-E031-4A2E-B16D-1D96757077F5Q34114297-1A59CC46-2FF5-4050-B29E-D59BA4E1B332Q34344469-8F4309CA-6043-40B5-AFCE-E39B75A83989Q34400424-5C9867DF-7C30-4F63-8F76-CC30AD62F2D7Q34446661-CBAD972F-9EB7-4BA8-8508-7EE5CF51E697Q34488796-9E51EDC8-C9AE-4479-A7B7-6D8B955BBA05Q34541113-FE9D9364-11C9-44DF-B539-8B9AE732498EQ34851245-20E925FB-1435-46C3-9F30-784BB0B7E3E6Q34973772-11B6E860-8E85-4120-94BC-A53BC2C4F236Q35078312-0A348188-385E-46B3-A423-8839C8E67FECQ35082533-8D7C2E49-099F-4920-BD5B-DA43C1D860DAQ35545757-2FB1047A-ADA5-4437-802A-30C60C636ADEQ35673157-C1617C9C-2C15-40B9-A9BA-64AEFF2372D4Q35794444-7A7E4734-C1D1-4698-96FA-66B9C058E719Q35925016-E1F0556A-0830-48DF-835F-0B3F6327FC71Q35961779-23AA713D-262D-4283-8F71-82B4EC0ED97BQ35996675-78350634-571F-402D-8385-C97883DE7C17Q36029619-1E0D2A89-2C6C-42C1-AFC4-DA9B340F9A43Q36094717-7E5A8A44-7B93-4181-A436-449C481A6E7EQ36154689-B212A5B3-EB31-419D-AECF-B46E0609232BQ36201257-A93D51CB-CC74-4EE3-9AA6-5BE0440B933EQ36366977-378C702A-46BE-4A67-BA4C-A0EFD30EB1A6Q36833122-05C41F8A-AAB9-46EF-A40A-C9EF9A2D651CQ36862420-1D41B572-3556-4986-8268-C20B5AC39848Q36892602-1C51AFA0-9D28-40C8-9EF2-7B3EF5F93438Q36914357-BBE7886E-8840-48CE-A6FE-73E47A568B0AQ36954396-645B338F-4A91-4F7E-9446-473076909F5CQ37355973-F0F6966C-17F9-47CA-8B26-56071EAD7BA4Q37429718-7A8A905E-379C-47F3-9354-88829E21374BQ37618829-3F2680CC-75E9-438B-93E9-5C97E2E9F8BCQ37644852-D1C12E43-472E-45CE-B76A-4F3DDFF80722Q38055164-20FC3FC9-593A-43E5-B03D-A34FD37483E9
P50
name
Martin Schrappe
@ast
Martin Schrappe
@en
Martin Schrappe
@es
Martin Schrappe
@nl
type
label
Martin Schrappe
@ast
Martin Schrappe
@en
Martin Schrappe
@es
Martin Schrappe
@nl
prefLabel
Martin Schrappe
@ast
Martin Schrappe
@en
Martin Schrappe
@es
Martin Schrappe
@nl
P214
P214
P31
P735
P7859
viaf-42945843